Physician profile
Edward Brajdic
NPI 1982617379
$1,413.01
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $571 · 2020: $189 · 2021: $86.98 · 2022: $107 · 2023: $367 · 2024: $92.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $459.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $417.09 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $166.47 | 2022-2024 | Miebo, Vyzulta |
| Alcon Vision LLC | $147.75 | 2019 | |
| Sun Pharmaceutical Industries INC. | $147.67 | 2020-2023 | Cequa |
| Lkc Technologies, INC. | $127.63 | 2023-2024 | |
| Maculogix, INC. | $126.73 | 2019-2021 | |
| Oyster Point Pharma, INC. | $77.64 | 2023 | Tyrvaya |
| Shire North American Group INC | $48.38 | 2019 | |
| Biotissue Holdings INC. | $32.63 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $30.06 | 2021 | |
| Abbvie INC. | $27.38 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.74 | 2021 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Kala Pharmaceuticals, INC. | $12.92 | 2020 | |
| Coopervision INC. | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Brajdic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.